Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Circ Heart Fail. 2019 Apr;12(4):e005565. doi: 10.1161/CIRCHEARTFAILURE.118.005565

Figure 5: Sacubitrilat ameliorates expression of myofibroblast markers in TGF-β1/AngII/ANF-stimulated nCF.

Figure 5:

A. Pretreatment with Sacubitrilat significantly decreases activation- and proliferation-associated gene expression in response to TGF-β1/AngII/ANF stress stimulus in neonatal CF. n = 3 each condition for all experiments. Two-way ANOVA with Tukey’s multiple comparisons test. * = p < 0.05 relative to vehicle control. & = p < 0.05 relative to the TGF-β1/AngII condition. ! = p < 0.05 relative to the TGF-β1/AngII/ANF condition. B. Pretreatment with valsartan alone only significantly alters proliferation-associated gene expression in neonatal CF, while valsartan + sacubitrilat also significantly inhibits some activation-associated genes. Two-way ANOVA with Tukey’s multiple comparisons test. * = p < 0.05 relative to vehicle control. & = p < 0.05 relative to the TGF-β1/AngII/ANF/valsartan condition. C. Valsartan and Sacubitrilat significantly inhibit ACTA2 induction by TGF-β1/AngII/ANF. One-way ANOVA with Tukey’s multiple comparison test. * = p < 0.05 relative to TGF-β1/AngII/ANF.